|
22 Companies |
|
21 Products |
|
21 Products |
|
24 Mechanisms of Action |
|
0 Trials |
|
313 News |
|
| 123456» |
- | Enrollment change, Trial withdrawal: Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus (clinicaltrials.gov) - Jan 11, 2024
P=N/A, N=0, Withdrawn, Sponsor: University of New Mexico
N=68 --> 0 | Completed --> Withdrawn
- | NN1213 / Novo Nordisk
Phase classification: PreColos: Feeding Bovine Colostrum to Preterm Infants (clinicaltrials.gov) - Jan 22, 2019
P=N/A, N=52, Completed, Sponsor: Per Torp Sangild
N=68 --> 0 | Completed --> Withdrawn Phase classification: P1/2 --> P=N/A
- | NN1213 / Novo Nordisk, Bexsero (meningococcal group B vaccine) / GSK
Trial completion: Investigating the Immune Response to 4CMenB in Infants (clinicaltrials.gov) - Oct 19, 2018
P4, N=187, Completed, Sponsor: University of Oxford
Phase classification: P1/2 --> P=N/A Active, not recruiting --> Completed
- | Cubicin (daptomycin) / Merck (MSD)
Trial completion date, Trial termination, Trial primary completion date, Gram positive: Daptomycin in Pediatric Patients With Bacterial Meningitis (clinicaltrials.gov) - Oct 11, 2018
P1, N=1, Terminated, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Trial completion date: Apr 2018 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Jun 2018; Insufficient patient recruitment
- | Phase classification: Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life (clinicaltrials.gov) - Oct 10, 2018
P3b, N=751, Completed, Sponsor: Novartis Vaccines
Trial completion date: Apr 2018 --> Jun 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Jun 2018; Insufficient patient recruitment Phase classification: P3 --> P3b
- | Phase classification: Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 (clinicaltrials.gov) - Jun 15, 2018
P2b, N=817, Completed, Sponsor: Novartis Vaccines
Phase classification: P3 --> P3b Phase classification: P2/3 --> P2b
- | NN1213 / Novo Nordisk
Trial completion: Auditory Brainstem Implantation in Young Children (clinicaltrials.gov) - Jun 6, 2018
P=N/A, N=5, Completed, Sponsor: University of North Carolina, Chapel Hill
Phase classification: P2/3 --> P2b Suspended --> Completed
- || Bexsero (meningococcal group B vaccine) / GSK
Trial completion date, IO biomarker: Investigating the Immune Response to 4CMenB in Infants (clinicaltrials.gov) - Mar 3, 2018
P4, N=160, Active, not recruiting, Sponsor: University of Oxford
Suspended --> Completed Trial completion date: Dec 2017 --> Jun 2018
- | Trial completion, Trial primary completion date: Col-Strepto B: Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis (clinicaltrials.gov) - Mar 2, 2018
P=N/A, N=949, Completed, Sponsor: Assistance Publique - H
Trial completion date: Dec 2017 --> Jun 2018 Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jun 2015
- | Trial completion: PreColos: Feeding Bovine Colostrum to Preterm Infants (clinicaltrials.gov) - Sep 28, 2017
P1/2, N=52, Completed, Sponsor: Per Torp Sangild
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Jun 2015 Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Bacterial Meningitis in Adults: Analysis of the Determinants of Mortality and Neurosensory Sequelae (clinicaltrials.gov) - Jul 5, 2017
P=N/A, N=527, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jun 2017
- | NN1213 / Novo Nordisk
Trial completion: Study and Surgical Treatment of Syringomyelia (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=50, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed | Trial primary completion date: Mar 2017 --> Jun 2017 Active, not recruiting --> Completed
- | Cubicin (daptomycin) / Merck (MSD)
Trial primary completion date, Gram positive: Daptomycin in Pediatric Patients With Bacterial Meningitis (clinicaltrials.gov) - Jun 8, 2017
P1, N=5, Recruiting, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- | rifampicin / Generic mfg.
Trial completion, Trial primary completion date: High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study (clinicaltrials.gov) - Jun 1, 2017
P2b, N=60, Completed, Sponsor: Universitas Padjadjaran
Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Nov 2016
- | Enrollment change, Trial withdrawal: A New Enzymatic Assay for Rapid Diagnosing of Central Nervous System Enteroviral Infection (clinicaltrials.gov) - May 16, 2017
P=N/A, N=0, Withdrawn, Sponsor: Shaare Zedek Medical Center
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Nov 2016 N=200 --> 0 | Active, not recruiting --> Withdrawn
- | Enrollment change, Trial primary completion date: Auditory Brainstem Implantation in Young Children (clinicaltrials.gov) - Apr 20, 2017
P=N/A, N=5, Suspended, Sponsor: University of North Carolina, Chapel Hill
N=200 --> 0 | Active, not recruiting --> Withdrawn N=10 --> 5 | Trial primary completion date: Apr 2023 --> Oct 2017
- | Trial suspension: Auditory Brainstem Implantation in Young Children (clinicaltrials.gov) - Apr 19, 2017
P=N/A, N=10, Suspended, Sponsor: University of North Carolina, Chapel Hill
N=10 --> 5 | Trial primary completion date: Apr 2023 --> Oct 2017 Recruiting --> Suspended
- | aspirin / Generic mfg.
Trial completion, Trial primary completion date: A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis (clinicaltrials.gov) - Mar 7, 2017
P2, N=120, Completed, Sponsor: Oxford University Clinical Research Unit, Vietnam
Recruiting --> Suspended Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2016
- ||||||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
Trial completion, Phase classification: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants (clinicaltrials.gov) - Jan 23, 2017
P3b, N=750, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2016 Active, not recruiting --> Completed | Phase classification: P3 --> P3b
- Enrollment closed: PreColos: Feeding Bovine Colostrum to Preterm Infants (clinicaltrials.gov) - Jan 4, 2017
P1/2, N=52, Active, not recruiting, Sponsor: Per Torp Sangild
Active, not recruiting --> Completed | Phase classification: P3 --> P3b Recruiting --> Active, not recruiting
- rifampicin / Generic mfg.
Enrollment closed, Trial primary completion date: High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study (clinicaltrials.gov) - Dec 9, 2016
P2b, N=60, Active, not recruiting, Sponsor: Universitas Padjadjaran
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2017
- ||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Enrollment change: Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine (clinicaltrials.gov) - Oct 27, 2016
P2, N=403, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2017 N=219 --> 403
- rifampicin / Generic mfg.
Phase classification: High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study (clinicaltrials.gov) - Oct 26, 2016
P2b, N=60, Recruiting, Sponsor: Universitas Padjadjaran
N=219 --> 403 Phase classification: P2/3 --> P2b
- ceftriaxone / Generic mfg., gentamicin sulfate / Generic mfg.
Trial completion, Enrollment change: Infaseme: Infant Severe Sepsis and Bacterial Meningitis in Malawi (clinicaltrials.gov) - Oct 26, 2016
P4, N=351, Completed, Sponsor: University of Malawi College of Medicine
Phase classification: P2/3 --> P2b Active, not recruiting --> Completed | N=238 --> 351
- ceftriaxone / Generic mfg.
Trial completion, Trial primary completion date: Pharmacological Study of High Doses of Ceftriaxone in Meningitidis (clinicaltrials.gov) - Oct 5, 2016
P4, N=198, Completed, Sponsor: Nantes University Hospital
Active, not recruiting --> Completed | N=238 --> 351 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2015
- lamivudine/stavudine/nevirapine / Hetero, Macleods, Cipla, Strides Pharma Science, Aurobindo, Emcure
Trial completion: Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa (clinicaltrials.gov) - Jul 18, 2016
P=N/A, N=54, Completed, Sponsor: University of Zimbabwe
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Dec 2015 Active, not recruiting --> Completed
- Trial primary completion date: Col-Strepto B: Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis (clinicaltrials.gov) - Jun 28, 2016
P=N/A, N=949, Active, not recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Trial primary completion date: Feb 2016 --> Jun 2016
- || Bexsero (meningococcal group B vaccine) / GSK
Trial primary completion date, IO biomarker: Investigating the Immune Response to 4CMenB in Infants (clinicaltrials.gov) - Jun 24, 2016
P4, N=160, Active, not recruiting, Sponsor: University of Oxford
Trial primary completion date: Feb 2016 --> Jun 2016 Trial primary completion date: Mar 2016 --> Jun 2016
- Enrollment closed: Bacterial Meningitis in Adults: Analysis of the Determinants of Mortality and Neurosensory Sequelae (clinicaltrials.gov) - Jun 18, 2016
P=N/A, N=527, Active, not recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Mar 2016 --> Jun 2016 Recruiting --> Active, not recruiting
- berubicin (RTA 744) / CNS Pharma, WPD Pharma
Trial termination: RTA 744 Injection in Patients With Leptomeningeal Disease (clinicaltrials.gov) - May 16, 2016
P1, N=7, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Completed --> Terminated; Study was closed due to loss of industry sponsorship
- | rifampicin / Generic mfg.
Enrollment open, Enrollment change, Trial primary completion date: High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study (clinicaltrials.gov) - May 16, 2016
P2/3, N=60, Recruiting, Sponsor: Universitas Padjadjaran
Completed --> Terminated; Study was closed due to loss of industry sponsorship Active, not recruiting --> Recruiting | N=32 --> 60 | Trial primary completion date: Jun 2016 --> Dec 2016
- aspirin / Generic mfg.
Enrollment closed: A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis (clinicaltrials.gov) - May 16, 2016
P2, N=120, Active, not recruiting, Sponsor: Oxford University Clinical Research Unit, Vietnam
Active, not recruiting --> Recruiting | N=32 --> 60 | Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Active, not recruiting
- Trial primary completion date: PreColos: Feeding Bovine Colostrum to Preterm Infants (clinicaltrials.gov) - May 12, 2016
P1/2, N=50, Recruiting, Sponsor: Per Torp Sangild
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Oct 2016
- | Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi, NN1213 / Novo Nordisk
Trial completion: Effect of Meningococcal Conjugate Vaccine on Meningococcal Carriage (clinicaltrials.gov) - Feb 27, 2016
P4, N=4000, Completed, Sponsor: Centers for Disease Control and Prevention
Trial primary completion date: Jun 2016 --> Oct 2016 Not yet recruiting --> Completed
- Trial primary completion date: Col-Strepto B: Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=900, Active, not recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Completed Trial primary completion date: Sep 2015 --> Feb 2016
- Cubicin (daptomycin) / Merck (MSD)
Enrollment open, Trial primary completion date, Gram positive: Daptomycin in Pediatric Patients With Bacterial Meningitis (clinicaltrials.gov) - Dec 12, 2015
P1, N=5, Recruiting, Sponsor: University Hospital Inselspital, Berne
Trial primary completion date: Sep 2015 --> Feb 2016 Suspended --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2016
- rifampicin / Generic mfg.
Enrollment closed, Enrollment change: High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study (clinicaltrials.gov) - Dec 4, 2015
P2/3, N=32, Active, not recruiting, Sponsor: Universitas Padjadjaran
Suspended --> Recruiting | Trial primary completion date: Apr 2015 --> Dec 2016 Recruiting --> Active, not recruiting | N=60 --> 32
- || Bexsero (meningococcal group B vaccine) / GSK
Trial primary completion date, IO biomarker: Investigating the Immune Response to 4CMenB in Infants (clinicaltrials.gov) - Nov 17, 2015
P4, N=160, Active, not recruiting, Sponsor: University of Oxford
Recruiting --> Active, not recruiting | N=60 --> 32 Trial primary completion date: Oct 2015 --> Mar 2016
- ||||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
Enrollment closed: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants (clinicaltrials.gov) - Nov 11, 2015
P3, N=750, Active, not recruiting, Sponsor: Novartis
Trial primary completion date: Oct 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- amikacin sulfate / Generic mfg.
Enrollment change, Gram negative: Amikacin Penetration Into the Cerebrospinal Fluid (clinicaltrials.gov) - Nov 10, 2015
P4, N=0, Withdrawn, Sponsor: Rambam Health Care Campus
Recruiting --> Active, not recruiting N=20 --> 0
- Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
Trial completion, Enrollment change, Trial primary completion date: Understanding the Immune Response to Two Different Meningitis Vaccines (clinicaltrials.gov) - Nov 9, 2015
P4, N=20, Completed, Sponsor: University of Oxford
N=20 --> 0 Active, not recruiting --> Completed | N=15 --> 20 | Trial primary completion date: Dec 2013 --> Apr 2013
- | Trial completion: An Alternative Booster Vaccine Against Meningitis and Ear Infections (clinicaltrials.gov) - Nov 9, 2015
P3, N=178, Completed, Sponsor: University of Oxford
Active, not recruiting --> Completed | N=15 --> 20 | Trial primary completion date: Dec 2013 --> Apr 2013 Active, not recruiting --> Completed
- | vancomycin / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
Trial completion, Trial primary completion date: Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections (clinicaltrials.gov) - Sep 25, 2015
P3, N=252, Completed, Sponsor: Rabin Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2014
- |||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK, Bexsero (meningococcal group B vaccine) / GSK
Trial primary completion date: Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants (clinicaltrials.gov) - Sep 24, 2015
P3, N=750, Recruiting, Sponsor: Novartis
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> May 2014 Trial primary completion date: Aug 2016 --> Nov 2016
- ||||||| Trial completion, Trial primary completion date: Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine (clinicaltrials.gov) - Sep 22, 2015
P3, N=2195, Completed, Sponsor: Beijing Minhai Biotechnology Co., Ltd
Trial primary completion date: Aug 2016 --> Nov 2016 Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Aug 2014
- ||||||| Trial completion, Trial primary completion date: Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine (clinicaltrials.gov) - Sep 22, 2015
P3, N=1260, Completed, Sponsor: Beijing Minhai Biotechnology Co., Ltd
Recruiting --> Completed | Trial primary completion date: Feb 2015 --> Aug 2014 Recruiting --> Completed | Trial primary completion date: Feb 2014 --> May 2015
- Trial completion, Trial primary completion date: Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos (clinicaltrials.gov) - Sep 16, 2015
P1, N=60, Completed, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Recruiting --> Completed | Trial primary completion date: Feb 2014 --> May 2015 Not yet recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2014
- ||| Bexsero (meningococcal group B vaccine) / GSK
Enrollment closed, IO biomarker: Investigating the Immune Response to 4CMenB in Infants (clinicaltrials.gov) - Aug 19, 2015
P4, N=160, Active, not recruiting, Sponsor: University of Oxford
Not yet recruiting --> Completed | Trial primary completion date: Jun 2014 --> Dec 2014 Not yet recruiting --> Active, not recruiting
- Trial primary completion date: An Alternative Booster Vaccine Against Meningitis and Ear Infections (clinicaltrials.gov) - Aug 13, 2015
P3, N=178, Active, not recruiting, Sponsor: University of Oxford
Not yet recruiting --> Active, not recruiting Trial primary completion date: Jun 2014 --> Aug 2013
- ||| Menveo (meningococcal-groups A, C, W-135 and Y oligosaccharide CRM197 conjugate vaccine) / GSK
Trial completion: Safety Surveillance of MenACWY-CRM Vaccine in Children (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=393, Completed, Sponsor: Novartis Vaccines
Trial primary completion date: Jun 2014 --> Aug 2013 Active, not recruiting --> Completed